PRME

MKT CAP:$670M

Prime Medicine, Inc.

Market Cap

$670M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.84+$0.31 (+8.87%)

Apr 21, 2026

Company Details

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse...

CEO

Allan Reine

IPO Date

Oct 20, 2022

Website

www.primemedicine.com

Key Metrics TTM

Revenue

$5M

+55.3% YoY

Net Income

-$201M

EPS (Diluted)

-$1.38

Free Cash Flow

-$167M

Revenue / Share

$0.03

Gross Margin

-58.1%

Operating Margin

-4498.1%

Net Margin

-4342.4%

FCF Margin

-3607.4%

P/S

144.6x

P/E

—

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Mar 3, 2026

$5M+55.3%EPS -$1.35

Q4 2025

Mar 3, 2026

$838.0K-61.6%EPS -$0.26

Q3 2025

Nov 7, 2025

$1M+486.1%EPS -$0.32

Q2 2025

Aug 7, 2025

$1MEPS -$0.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$60M
Q1 22	$0	$0	-$20M
Q2 22	$0	$0	-$26M
Q4 22	$0	$0	-$39M
Q1 23	$0	$0	-$40M
Q2 23	$0	$0	-$45M
Q3 23	$0	$0	-$51M
Q4 23	$0	$0	-$68M
Q1 24	$591.0K	-$724.0K	-$48M
Q2 24	$0	$0	-$56M
Q3 24	$209.0K	$209.0K	-$54M
Q4 24	$2M	$2M	-$44M
Q1 25	$1M	$1M	-$52M
Q2 25	$1M	-$749.0K	-$53M
Q3 25	$1M	-$43M	-$54M
Q4 25	$838.0K	$39M	-$49M

Valuation

Quarter	P/S	P/E
Q4 21	—	—
Q1 22	—	—
Q2 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	1133.4x	—
Q2 24	1133.4x	—
Q3 24	837.3x	—
Q4 24	224.5x	—
Q1 25	174.2x	—
Q2 25	135.0x	—
Q3 25	112.1x	—
Q4 25	144.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$13M	-$14M
Q1 22	-$51M	-$52M
Q2 22	-$20M	-$25M
Q4 22	-$31M	-$36M
Q1 23	-$42M	-$44M
Q2 23	-$41M	-$43M
Q3 23	-$39M	-$42M
Q4 23	-$44M	-$46M
Q1 24	-$68M	-$70M
Q2 24	-$45M	-$47M
Q3 24	-$26M	-$27M
Q4 24	$16M	$14M
Q1 25	-$49M	-$51M
Q2 25	-$41M	-$43M
Q3 25	-$35M	-$35M
Q4 25	-$37M	-$38M

Capital Expenditures

Quarter	CapEx
Q4 21	$382.0K
Q1 22	$2M
Q2 22	$5M
Q4 22	$5M
Q1 23	$2M
Q2 23	$2M
Q3 23	$3M
Q4 23	$2M
Q1 24	$2M
Q2 24	$2M
Q3 24	$1M
Q4 24	$2M
Q1 25	$2M
Q2 25	$2M
Q3 25	$247.0K
Q4 25	$290.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+2213.3%
Q1 22	—	+234.1%
Q2 22	—	+228.2%
Q4 22	—	+271.0%
Q1 23	—	-33.4%
Q2 23	—	+127.4%
Q3 23	—	+95.6%
Q4 23	—	+75.9%
Q1 24	—	+22.2%
Q2 24	—	+23.0%
Q3 24	—	+5.8%
Q4 24	—	-31.8%
Q1 25	+146.0%	+10.0%
Q2 25	—	-2.1%
Q3 25	+486.1%	+1.4%
Q4 25	-61.6%	+6.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$1M	—
Q1 22	$1M	—
Q2 22	$1M	—
Q4 22	$3M	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$5M	881.4%
Q2 24	$0	—
Q3 24	$7M	3266.5%
Q4 24	$6M	272.1%
Q1 25	$6M	390.7%
Q2 25	$6M	567.3%
Q3 25	$13M	1040.6%
Q4 25	$5M	538.8%

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$53M	$7M
Q1 22	$14M	$6M
Q2 22	$19M	$7M
Q4 22	$29M	$10M
Q1 23	$31M	$9M
Q2 23	$35M	$11M
Q3 23	$41M	$10M
Q4 23	$41M	$13M
Q1 24	$38M	$11M
Q2 24	$43M	$13M
Q3 24	$40M	$14M
Q4 24	$34M	$12M
Q1 25	$41M	$13M
Q2 25	$41M	$13M
Q3 25	$44M	$11M
Q4 25	$35M	$15M

Revenue Segments

Quarter	Reportable Segment
Q1 25	$1M
Q2 25	$1M
Q3 25	$1M
Q4 25	$838.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$164M	$47M	$211M
Q2 22	$92M	$88M	$181M
Q3 22	$48M	$99M	$147M
Q4 22	$188M	$106M	$294M
Q1 23	$133M	$116M	$250M
Q2 23	$121M	$87M	$208M
Q3 23	$44M	$121M	$165M
Q4 23	$42M	$80M	$122M
Q1 24	$94M	$117M	$211M
Q2 24	$56M	$107M	$163M
Q3 24	$118M	$58M	$176M
Q4 24	$182M	$8M	$190M
Q1 25	$92M	$52M	$144M
Q2 25	$54M	$48M	$102M
Q3 25	$71M	$137M	$208M
Q4 25	$63M	$115M	$178M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	96M	0.0%	0.0%
Q1 22	96M	0.0%	0.0%
Q2 22	96M	0.0%	0.0%
Q4 22	97M	+1.5%	+1.5%
Q1 23	89M	-8.4%	-7.0%
Q2 23	90M	+1.6%	-5.5%
Q3 23	92M	+1.5%	-4.1%
Q4 23	97M	+6.0%	+0.2%
Q1 24	104M	+7.3%	+17.3%
Q2 24	119M	+14.1%	+31.7%
Q3 24	120M	+0.5%	+30.4%
Q4 24	119M	-1.0%	+21.8%
Q1 25	131M	+10.4%	+25.3%
Q2 25	129M	-1.3%	+8.4%
Q3 25	161M	+24.2%	+34.0%
Q4 25	149M	-7.3%	+25.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	—	—
Q1 22	—	—
Q2 22	—	—
Q4 22	$0	175
Q1 23	$0	175
Q2 23	$0	175
Q3 23	$0	175
Q4 23	$0	234
Q1 24	$2.5K	234
Q2 24	$0	234
Q3 24	$893	234
Q4 24	$10.2K	214
Q1 25	$6.8K	214
Q2 25	$5.2K	214
Q3 25	$5.7K	214
Q4 25	$8	100K

Revenue / Employee